Influenza is generally a self-limited illness, but complications including pneumonia, respiratory failure, and death can occur, especially in persons at increased risk (see Table 1).
TREATMENT OF INFLUENZA — Three neuraminidase inhibitors (oral oseltamivir, IV peramivir, and inhaled zanamivir) and the oral cap-dependent endonuclease inhibitor baloxavir marboxil are available in the US and are recommended for treatment of influenza this season (see Table 2).1
Antiviral...
RELEASE
Sebetralstat (Ekterly – Kalvista), an oral plasma kallikrein inhibitor, has been approved by the FDA for treatment of acute hereditary angioedema (HAE) attacks in patients ≥12 years old. It is the first oral drug to be approved in the US for this indication. The intravenous C1 esterase inhibitors (C1INHs) Berinert and Ruconest, the subcutaneous plasma kallikrein inhibitor ecallantide (Kalbitor), and the subcutaneous bradykinin B2 receptor antagonist icatibant (Firazyr) have been available for years for on-demand treatment of HAE attacks; all of these drugs except ecallantide can be self-administered, but treatment delays are common.1-3
THE DISEASE ― HAE is an autosomal dominant disorder with an estimated prevalence of 1:50,000. It is characterized by recurrent, often unpredictable, painful attacks of angioedema, typically involving the skin …